Jasenka Piljac, PhD

Emerging studies aim to better understand therapeutic interventions that may mitigate increased CVD risk in patients with RA.

The realization that IL-6 is implicated in many pathologic features of RA has prompted the search for IL-6-blocking agents as therapeutic options for this condition.